ravulizumab

CHEBI:CHEBI_749929

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2461140
generic_name
ravulizumab 100 mg/ml
product_type
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
dosage_form
SOLUTION, CONCENTRATE
active_ingredient_strength
1100 mg/11mL
route
INTRAVENOUS
marketing_start_date
20170815
marketing_category
DRUG FOR FURTHER PROCESSING
nui
N0000175974
pharm_class_epc
Complement Inhibitor [EPC]
pharm_class
Complement Inhibitors [MoA]
pharm_class_moa
Complement Inhibitors [MoA]
package_marketing_start_date
15-AUG-17
labeler_name
Alexion Pharmaceuticals Inc.
product_ndc
42098-0004
spl_id
258c9695-fe29-bec9-e063-6294a90a0bbb
active_ingredient_name
RAVULIZUMAB-CWVZ
package_ndc
42098-0004-4
package_description
12000 mL in 1 BAG (42098-0004-4)
brand_name
Ultomiris
brand_name_base
Ultomiris
application_number
BLA761108
manufacturer_name
Alexion Pharmaceuticals Inc.
unii
C3VX249T6L
spl_set_id
a9a590d9-0217-43c7-908d-e62a71279791
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class